Ascending Dose Study of CT1812 in Healthy Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study
will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a
multiple ascending dose (MAD) phase "Part B". In Part A, subjects will receive one dose of
study drug. In Part B, subjects within a cohort will receive the same dose daily for 14 days.
In both parts, sequential cohorts will be exposed to increasing doses of CT1812 in order to
identify the maximum tolerated dose (MTD).